Core Viewpoint - The company has made progress in the registration of its product, cyhalofop-butyl, both domestically and internationally, indicating a shift towards a combined model of innovation and imitation in its business strategy [2] Group 1: Product Development - The company has obtained some foreign registration certificates for its cyhalofop-butyl product [2] - Domestic registration has been completed and is awaiting certification [2] Group 2: Strategic Partnerships - The company is collaborating with Syngenta and UPL to expand its global market presence [2] - This partnership is seen as an opportunity to facilitate the commercialization of innovative products [2] Group 3: Business Model Transformation - The company is transitioning from a traditional imitation model to a combined model of innovation and imitation [2]
泰禾股份：环丙氟虫胺产品已经取得部分国外登记证